<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Bolar</title>
	<atom:link href="http://www.tapanray.in/tag/bolar/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Will the ‘Bayer–Cipla case’ now put the ‘Bolar Provision’ under judicial scrutiny?</title>
		<link>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny</link>
		<comments>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 01:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Bayer–Cipla]]></category>
		<category><![CDATA[Bolar]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[judicial]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Provision]]></category>
		<category><![CDATA[put]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=748</guid>
		<description><![CDATA[To enable the domestic pharmaceutical industry gaining a critical mass and cater to the pressing healthcare needs of the nation, in 1970 product patent act was abolished by the government of India. This immensely helped the domestic companies to launch &#8230; <a href="http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
